Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Abemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer

September 9th 2022

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers

September 8th 2022

Expert perspectives on how to best manage adverse events associated with trastuzumab emtansine while treating patients with breast or gastric cancers.

Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers

September 8th 2022

Shared insight on the clinical utility of trastuzumab emtansine in the second- and third-line settings of breast and gastric cancers.

Future Directions in HR+ Breast Cancer Management

September 7th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.

Clinical and Practical Implications of the Breast Cancer Index

September 7th 2022

A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.

FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer

September 5th 2022

Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.

Sacituzumab Govitecan Provides PFS Benefit Vs Chemotherapy in HR+/HER2– Breast Cancer

September 2nd 2022

Sacituzumab govitecan displayed encouraging progression-free survival rates compared with single-agent chemotherapy in patients with locally recurrent inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer, according to findings from the phase 3 TROPiCS-02 study.

Social Determinants and Genetics Work in Tandem to Drive Disparities in Breast Cancer Care

September 2nd 2022

Adana A.M. Llanos, PhD, MPH, discusses key research on the social and biological factors that influence disparities in breast cancer, how these factors work in tandem to affect patient outcomes, and how this knowledge can be deployed in the real world.

Metastatic Breast Cancer Enters a New Era of HER2 Classification

September 2nd 2022

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.

Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy

September 1st 2022

Shifting focus to a patient profile of HER2+ metastatic breast cancer treated with trastuzumab emtansine, oncology nurse experts review risk of peripheral neuropathy and its management.

Sequencing Therapy in MBC in Second Line and Beyond

September 1st 2022

Closing out their conversation on the first patient profile, oncology nurse experts consider sequencing therapy following trastuzumab deruxtecan in both breast and GI cancers.

Audience Q&A: Future Directions in Breast Cancer Care

August 31st 2022

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.

Trastuzumab Deruxtecan Approval for HER2-Low Breast Cancer Sparks Bright Future for ADCs

August 29th 2022

Shanu Modi, MD, discusses the significance of the approval of trastuzumab deruxtecan for patients with HER2-low breast cancer.

Multidisciplinary Management Stands at the Forefront of Breast Cancer Treatment

August 29th 2022

Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.

Emerging Data are Expanding Treatment Options, Extending Survival Across Breast Cancer Subtypes

August 29th 2022

Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings.

Biomarkers for Selection of Extended Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.

Data on Extended Adjuvant Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.

Olaparib Approved in Japan for BRCA-Mutated, HER2-Negative, High-Risk Early Breast Cancer

August 25th 2022

The Japanese Ministry of Health, Labor, and Welfare has approved olaparib as an adjuvant treatment for patients with BRCA-mutated, HER2-negative, high-risk early breast cancer.

Selecting Appropriate Patients with MBC for T-DXd and Counseling for AEs

August 25th 2022

Comprehensive insight to the selection and education of patients for whom ADC therapy is an option in breast or gastric cancers, with regard for pulmonary risk status.

Management of Interstitial Lung Disease Related to T-DXd in Breast or Gastric Cancers

August 25th 2022

Focused conversation on the occurrence of interstitial lung disease in patients on antibody drug conjugate therapy for breast or gastric cancers.